Sex-Based Differences and Risk Factors for Comorbid Nonalcoholic Fatty Liver Disease in Patients with Bipolar Disorder: A Cross-Sectional Retrospective Study

References

• Martinez-Aran A, Vieta E, Torrent C, et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007;9(1–2):103–113. doi:10.1111/j.1399-5618.2007.00327.x
   PubMed Web of Science ®Google Scholar
• Bauer MS. Bipolar Disorder. Ann Intern Med. 2022;175(7):Itc97–itc112. doi:10.7326/AITC202207190
   PubMed Web of Science ®Google Scholar
• Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry. 2011;16(12):1234–1246. doi:10.1038/mp.2010.101
   PubMed Web of Science ®Google Scholar
• Silarova B, Giltay EJ, Van Reedt Dortland A, et al. Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls. J Psychosom Res. 2015;78(4):391–398. doi:10.1016/j.jpsychores.2015.02.010
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170(3):265–274. doi:10.1176/appi.ajp.2012.12050620
   PubMed Web of Science ®Google Scholar
• Godin O, Leboyer M, Belzeaux R, et al. Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. Acta Psychiatr Scand. 2021;143(1):82–91. doi:10.1111/acps.13239
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhang X, Liu Y, Wang Y. Prevalence and Risk Factors of Comorbid Obesity in Chinese Patients with Bipolar Disorder. Diabetes Metab Syndr Obes. 2023;16:1459–1469. doi:10.2147/DMSO.S404127
   PubMed Web of Science ®Google Scholar
• Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20(3):131–137. doi:10.1080/10401230802177722
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–910. doi:10.1016/S2213-8587(14)70032-4
   PubMed Web of Science ®Google Scholar
• Eslam M, George J. Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement”: bringing evidence to the NAFLD-MAFLD debate. J Hepatol. 2020;73(6):1575. doi:10.1016/j.jhep.2020.07.045
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–755 e743. doi:10.1016/j.cgh.2018.05.057
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Ma Q, Yang F, Ma B, et al. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study. Hepatol Int. 2021;15(1):127–136. doi:10.1007/s12072-020-10132-z
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou J, Wang W, et al. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: a Systematic Review and Meta-Analysis. Hepatology. 2019;70(4):1119–1133. doi:10.1002/hep.30702
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. doi:10.1002/hep.29466
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Sinn DH, Kang D, Chang Y, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2017;66(2):323–329. doi:10.1136/gutjnl-2016-311854
   PubMed Web of Science ®Google Scholar
• Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):425–439. doi:10.1038/s41575-018-0010-0
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021
   PubMed Web of Science ®Google Scholar
• Mahady SE, George J. Predicting the future burden of NAFLD and NASH. J Hepatol. 2018;69(4):774–775. doi:10.1016/j.jhep.2018.06.025
   PubMed Web of Science ®Google Scholar
• Buoli M, Cesana BM, Dell’Osso B, et al. Gender-related differences in patients with bipolar disorder: a nationwide study. CNS Spectr. 2019;24(6):589–596. doi:10.1017/S1092852918001529
   PubMed Web of Science ®Google Scholar
• Suominen K, Mantere O, Valtonen H, Arvilommi P, Leppämäki S, Isometsä E. Gender differences in bipolar disorder type I and II. Acta Psychiatr Scand. 2009;120(6):464–473. doi:10.1111/j.1600-0447.2009.01407.x
   PubMed Web of Science ®Google Scholar
• Cotton SM, Lambert M, Schimmelmann BG, et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res. 2009;114(1–3):17–24. doi:10.1016/j.schres.2009.07.002
   PubMed Web of Science ®Google Scholar
• Rietschel L, Lambert M, Karow A, et al. Clinical high risk for psychosis: gender differences in symptoms and social functioning. Early Interv Psychiatry. 2017;11(4):306–313. doi:10.1111/eip.12240
   PubMed Web of Science ®Google Scholar
• Menculini G, Steardo L Jr, Sciarma T, et al. Sex Differences in Bipolar Disorders: impact on Psychopathological Features and Treatment Response. Front Psychiatry. 2022;13:926594. doi:10.3389/fpsyt.2022.926594
   PubMed Web of Science ®Google Scholar
• Patel RS, Virani S, Saeed H, Nimmagadda S, Talukdar J, Youssef NA. Gender Differences and Comorbidities in U.S. Adults with Bipolar Disorder. Brain Sci. 2018;8(9):168. doi:10.3390/brainsci8090168
   PubMed Web of Science ®Google Scholar
• Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of Overweight and Obesity in People With Severe Mental Illness: systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:769309. doi:10.3389/fendo.2021.769309
   PubMedGoogle Scholar
• Li Q, Chen D, Liu T, et al. Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia. J Clin Psychopharmacol. 2016;36(6):643–648. doi:10.1097/JCP.0000000000000594
   PubMed Web of Science ®Google Scholar
• Baskaran A, Cha DS, Powell AM, Jalil D, McIntyre RS. Sex differences in rates of obesity in bipolar disorder: postulated mechanisms. Bipolar Disord. 2014;16(1):83–92. doi:10.1111/bdi.12141
   PubMed Web of Science ®Google Scholar
• Li X, Gao Y, Wang Y, Wang Y, Wu Q. Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: a Cross-Sectional Retrospective Study. Neuropsychiatr Dis Treat. 2023;19:379–389. doi:10.2147/NDT.S398385
   PubMed Web of Science ®Google Scholar
• Dilling H, Dittmann V. Psychiatric diagnosis following the 10th revision of the International Classification of Diseases (ICD-10). Nervenarzt. 1990;61(5):259–270.
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85. doi:10.1111/jgh.13857
   PubMed Web of Science ®Google Scholar
• Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304. doi:10.1089/met.2008.0034
   PubMedGoogle Scholar
• Hsu JH, Chien IC, Lin CH. Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study. Gen Hosp Psychiatry. 2015;37(4):294–298. doi:10.1016/j.genhosppsych.2015.04.003
   PubMed Web of Science ®Google Scholar
• Hsu JH, Chien IC, Lin CH. Increased risk of ischemic heart disease in patients with bipolar disorder: a population-based study. J Affect Disord. 2021;281:721–726. doi:10.1016/j.jad.2020.11.083
   PubMed Web of Science ®Google Scholar
• Soto-Angona O, Anmella G, Valdes-Florido MJ, et al. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med. 2020;18(1):261. doi:10.1186/s12916-020-01713-8
   PubMed Web of Science ®Google Scholar
• Mosolov SN, Fedorova EY. The risk of developing cardiovascular disease in bipolar disorder. Clinical and social factors. Ter Arkh. 2021;93(12):1556–1561. doi:10.26442/00403660.2021.12.201175
   PubMed Web of Science ®Google Scholar
• Rossom RC, Hooker SA, O’Connor PJ, Crain AL, Sperl-Hillen JM. Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder. J Am Heart Assoc. 2022;11(6):e021444. doi:10.1161/JAHA.121.021444
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab. 2018;27(1):22–41. doi:10.1016/j.cmet.2017.08.002
   PubMed Web of Science ®Google Scholar
• Xie J, Huang H, Liu Z, et al. The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study. Hepatology. 2022.
   Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a Sexual Dimorphic Disease: role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017;34(6):1291–1326. doi:10.1007/s12325-017-0556-1
   PubMed Web of Science ®Google Scholar
• Burra P, Bizzaro D, Gonta A, et al. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41(8):1713–1733. doi:10.1111/liv.14943
   PubMed Web of Science ®Google Scholar
• Purcell-Huynh DA, Farese RV Jr, Johnson DF, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95(5):2246–2257. doi:10.1172/JCI117915
   PubMed Web of Science ®Google Scholar
• Zhao W, Li J, Zhang X, et al. Apolipoprotein B and renal function: across-sectional study from the China health and nutrition survey. Lipids Health Dis. 2020;19(1):110. doi:10.1186/s12944-020-01241-7
   PubMed Web of Science ®Google Scholar
• Han SJ, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ. Apolipoprotein B Levels Predict Future Development of Hypertension Independent of Visceral Adiposity and Insulin Sensitivity. Endocrinol Metab. 2020;35(2):351–358. doi:10.3803/EnM.2020.35.2.351
   Google Scholar
• Koskinen J, Magnussen CG, Wurtz P, et al. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study. Eur J Prev Cardiol. 2012;19(6):1296–1303. doi:10.1177/1741826711425343
   PubMed Web of Science ®Google Scholar
• Zhang XL, Wang TY, Targher G, Byrne CD, Zheng MH. Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. Diabetes Metab J. 2022;46(3):391–401. doi:10.4093/dmj.2022.0048
   PubMed Web of Science ®Google Scholar
• Mascaró CM, Bouzas C, Tur JA. Association between Non-Alcoholic Fatty Liver Disease and Mediterranean Lifestyle: a Systematic Review. Nutrients. 2021;14(1):49. doi:10.3390/nu14010049
   PubMed Web of Science ®Google Scholar
• Jung CH, Yu JH, Bae SJ, et al. Serum gamma-glutamyltransferase is associated with arterial stiffness in healthy individuals. Clin Endocrinol (Oxf). 2011;75(3):328–334. doi:10.1111/j.1365-2265.2011.04060.x
   PubMed Web of Science ®Google Scholar
• Ren J, Sun J, Ning F, et al. Gender differences in the association of hypertension with gamma-glutamyltransferase and alanine aminotransferase levels in Chinese adults in Qingdao, China. J Am Soc Hypertens. 2015;9(12):951–958. doi:10.1016/j.jash.2015.09.014
   PubMed Web of Science ®Google Scholar
• Cho HS, Lee SW, Kim ES, et al. Clinical significance of serum bilirubin and gamma-glutamyltransferase levels on coronary atherosclerosis assessed by multidetector computed tomography. Nutr Metab Cardiovasc Dis. 2015;25(7):677–685. doi:10.1016/j.numecd.2015.03.014
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Cakr H, et al. Sex-Specific Predictors of Metabolic Syndrome Independent of Its Components. J Investig Med. 2015;63(6):796–801. doi:10.1097/JIM.0000000000000203
   PubMed Web of Science ®Google Scholar
• Hu H, Han Y, Cao C, He Y. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. J Transl Med. 2022;20(1):398. doi:10.1186/s12967-022-03611-4
   PubMed Web of Science ®Google Scholar
• Guo W, Lu J, Qin P, et al. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. Lipids Health Dis. 2020;19(1):218. doi:10.1186/s12944-020-01393-6
   PubMed Web of Science ®Google Scholar
• Lin IT, Lee MY, Wang CW, Wu DW, Chen SC. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population. Int J Environ Res Public Health. 2021;18(3). doi:10.3390/ijerph18030857
   Web of Science ®Google Scholar
• Park K, Ahn CW, Lee SB, et al. Elevated TyG Index Predicts Progression of Coronary Artery Calcification. Diabetes Care. 2019;42(8):1569–1573. doi:10.2337/dc18-1920
   PubMed Web of Science ®Google Scholar
• Tai S, Fu L, Zhang N, et al. Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):161. doi:10.1186/s12933-022-01599-1
   PubMed Web of Science ®Google Scholar
• Wang X, Xu W, Song Q, et al. Association between the triglyceride-glucose index and severity of coronary artery disease. Cardiovasc Diabetol. 2022;21(1):168. doi:10.1186/s12933-022-01606-5
   PubMed Web of Science ®Google Scholar
• Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16(6):377–386. doi:10.1038/s41575-019-0144-8
   PubMed Web of Science ®Google Scholar
• Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol. 2019;71(1):212–221. doi:10.1016/j.jhep.2019.03.004
   PubMed Web of Science ®Google Scholar